Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients.

Onsum MD, Geretti E, Paragas V, Kudla AJ, Moulis SP, Luus L, Wickham TJ, McDonagh CF, Macbeath G, Hendriks BS.

Am J Pathol. 2013 Nov;183(5):1446-60. doi: 10.1016/j.ajpath.2013.07.015. Epub 2013 Sep 11.

PMID:
24035511
2.

A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.

Nitta H, Kelly BD, Padilla M, Wick N, Brunhoeber P, Bai I, Singh S, Ranger-Moore J, Bieniarz C, Tsuda H, Grogan TM.

Diagn Pathol. 2012 May 30;7:60. doi: 10.1186/1746-1596-7-60.

3.

A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.

Nishida Y, Kuwata T, Nitta H, Dennis E, Aizawa M, Kinoshita T, Ohtsu A, Ochiai A.

Gastric Cancer. 2015 Jul;18(3):458-66. doi: 10.1007/s10120-014-0394-7. Epub 2014 Jun 11.

PMID:
24917219
4.

Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.

Gatza ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR, Chi JT.

Breast Cancer Res. 2011 Jun 7;13(3):R62. doi: 10.1186/bcr2899.

5.

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Seguí MÁ, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M.

BMC Med Genomics. 2012 Oct 4;5:44. doi: 10.1186/1755-8794-5-44.

6.
7.

Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.

Yang J, Luo H, Li Y, Li J, Cai Z, Su X, Dai D, Du W, Chen T, Chen M.

Cell Biochem Biophys. 2012 Jan;62(1):221-8. doi: 10.1007/s12013-011-9286-1.

PMID:
21927816
8.
9.

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.

Seol H, Lee HJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Park SY.

Mod Pathol. 2012 Jul;25(7):938-48. doi: 10.1038/modpathol.2012.36. Epub 2012 Mar 2.

11.

Image cytometric HER2 in gastric carcinoma: is a new algorithm needed?

Ormenisan C, Wang J, Lawson D, Cohen C.

Appl Immunohistochem Mol Morphol. 2013 Oct;21(5):414-9. doi: 10.1097/PAI.0b013e31827955c8.

PMID:
23197004
12.

Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.

Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V.

Arch Pathol Lab Med. 2011 Nov;135(11):1460-5. doi: 10.5858/arpa.2010-0541-OA.

PMID:
22032573
13.

HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.

Fusco N, Rocco EG, Del Conte C, Pellegrini C, Bulfamante G, Di Nuovo F, Romagnoli S, Bosari S.

Mod Pathol. 2013 Jun;26(6):816-24. doi: 10.1038/modpathol.2012.228. Epub 2013 Jan 25.

14.

A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.

Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, DeFazio-Eli L, Pidaparthi S, Badal Y, Wallweber G, Chen L, Williams S, Tahir H, Larson J, Goodman L, Whitcomb J, Petropoulos C, Winslow J.

Diagn Mol Pathol. 2009 Mar;18(1):11-21. doi: 10.1097/PDM.0b013e31818cbdb2.

PMID:
19214113
15.

Quantitative detection of HER2 protein concentration in breast cancer tissue does not increase the number of patients eligible for adjuvant HER2-targeted therapy.

Bechmann T, Olsen DA, Jakobsen EH, Madsen JS, Brandslund I, Jylling AM, Steffensen KD, Jakobsen A.

Oncol Rep. 2013 Apr;29(4):1475-82. doi: 10.3892/or.2013.2289. Epub 2013 Feb 15.

PMID:
23417164
16.
17.

A study of HER2 gene amplification and protein expression in gastric cancer.

Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG, Salto-Tellez M.

J Clin Pathol. 2010 Sep;63(9):839-42. doi: 10.1136/jcp.2010.076570. Epub 2010 Aug 9.

PMID:
20696687
18.

Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens.

Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C.

Diagn Pathol. 2013 Feb 4;8:17. doi: 10.1186/1746-1596-8-17.

19.

Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).

Kiyose S, Igarashi H, Nagura K, Kamo T, Kawane K, Mori H, Ozawa T, Maeda M, Konno K, Hoshino H, Konno H, Ogura H, Shinmura K, Hattori N, Sugimura H.

Pathol Int. 2012 Nov;62(11):728-34. doi: 10.1111/j.1440-1827.2012.02862.x.

PMID:
23121603
20.

Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?

Park YS, Hwang HS, Park HJ, Ryu MH, Chang HM, Yook JH, Kim BS, Jang SJ, Kang YK.

Hum Pathol. 2012 Mar;43(3):413-22. doi: 10.1016/j.humpath.2011.05.019. Epub 2011 Aug 19.

PMID:
21855114
Items per page

Supplemental Content

Write to the Help Desk